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Objective: To evaluate the prevalence of systemic and localized infection by Candida species
and its possible association with demographic, clinical and laboratory manifestations and
therapy in patients with rheumatic diseases taking TNF blockers.
Methods: Consecutive patients with rheumatic diseases receiving anti-TNF agents were
included. The following risk factors up to four weeks prior to the study were analyzed: use
of  antibiotics, immunosuppressant drugs, hospitalization and invasive procedures. All sub-
jects were evaluated for clinical complaints; speciﬁc blood cultures were obtained for fungi
and  blood samples were collected for Candida spp. detection by polymerase chain reaction.
Results: 194 patients [67 with rheumatoid arthritis (RA), 47 with ankylosing spondylitis (AS),
36  with juvenile idiopathic arthritis (JIA), 28 with psoriatic arthritis and 16 with other con-
ditions] were included. The average age of patients was 42 ± 16 years, with 68 (35%) male
and mean disease duration of 15 ± 10 years. Sixty-four (33%) patients were receiving adal-
imumab, 59 (30%) etanercept and 71 (36%) inﬂiximab. Eighty-one percent of patients were
concomitantly taking immunosuppressant drugs. At the time of the study, only one (0.5%)
patient had localized fungal infection (vaginal candidiasis). None of the patients included
had  systemic candidiasis with positive blood cultures for fungi or PCR positive for Candida
spp.  in peripheral blood sample.
Conclusions: This was the ﬁrst study to assess the prevalence of invasive and localized fun-
gal  disease by Candida in a signiﬁcant number of patients with rheumatic diseases on
anti-TNF therapy, and demonstrated low risk of candidiasis, despite the high prevalenceof  immunosuppressive drug use.
©  2015 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infecc¸ão  sistêmica  e  localizada  por  Candida  spp. em  pacientes
reumatológicos  em  terapia  anti-TNF
Palavras-chave:
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Espondilite anquilosante
r  e  s  u  m  o
Objetivo: Avaliar a prevalência de infecc¸ão sistêmica e localizada por Candida spp.  e sua
possível associac¸ão com dados demográﬁcos, manifestac¸ões clínicas e laboratoriais e ter-
apêutica em pacientes com doenc¸as reumatológicas em uso de anti-TNF.
Métodos: Foram incluídos pacientes consecutivos com doenc¸as reumatológicas em uso de
agentes anti-TNF. Foram analisados os seguintes fatores de risco até quatro semanas antes
do  estudo: uso de antibioticoterapia, imunossupressores, hospitalizac¸ão e procedimentos
invasivos. Todos foram avaliados para queixas clinicas, coletaram hemocultura especíﬁca
para  fungos e amostras de sangue para pesquisa de Candida spp. por reac¸ão em cadeia de
polimerase.
Resultados: Foram incluídos 194 pacientes [67 com artrite reumatoide (AR), 47 espondilite
anquilosante (EA), 36 artrite idiopática juvenil (AIJ), 28 artrite psoriásica e 16 outros].
A  média de idade era de 42 ± 16 anos, com 68 (35%) do sexo masculino e média de durac¸ão
de  doenc¸a de 15 ± 10 anos; 64 (33%) pacientes usavam adalimumabe, 59 (36%) etanercepte e
71  (36%) inﬂiximabe; 81% faziam uso concomitante de imunossupressores. No momento do
estudo, apenas um (0,5%) paciente apresentou infecc¸ão fúngica localizada (candidíase vagi-
nal).  Nenhum dos pacientes incluídos apresentou candidíase sistêmica com hemocultura
positiva para fungos ou PCR positiva para Candida spp.  em amostra de sangue periférico.
Conclusões: Este foi o primeiro estudo que avaliou prevalência de doenc¸a fúngica invasiva e
localizada por Candida em um expressivo número de pacientes reumatológicos em terapia
anti-TNF e demonstrou baixo risco de candidíase, apesar da alta prevalência de uso de
imunossupressores.
© 2015 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma  licenc¸a CC
BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients with RA and JIA, and Bath Ankylosing Spondyli-ntroduction
nti-TNF therapy has been widely used in patients with
heumatic diseases who do not respond to disease-modifying
ntirheumatic drugs (DMARDs), with a signiﬁcant improve-
ent in prognosis. However, at the same time, concerns
elated to immunosuppression due to such therapy emerge,
enerating increasing reports of infections by opportunistic
ungal agents such as Candida spp.1
This fungus can produce a wide spectrum of clinical pre-
entations, ranging from superﬁcial mucocutaneous disease
o severe invasive infections. Systemic candidiasis affects
ainly patients treated with immunosuppressive drugs,
ncluding glucocorticoids and broad-spectrum antibiotics, and
ubmitted to invasive procedures, with high mortality rates.2–5
Candidemia has previously been reported in small series of
atients on biological therapy with TNF blockers, but a clear
ausal relationship has not been established.6,7 In addition,
here are rare reports of systemic infection by Candida spp. in
atients with rheumatic diseases.8,9
The aim of this study was to determine the prevalence of
ystemic and localized candidiasis and its possible association
ith demographics, clinical and laboratory manifestations,
nd therapy in patients with rheumatic diseases in use of
nti-TNF agents.Materials  and  methods
Consecutive patients with a diagnosis of rheumatoid arthritis
(RA),10 ankylosing spondylitis (AS),11 psoriatic arthritis (PsA),12
juvenile idiopathic arthritis (JIA),13 and with other conditions
(Behcet’s disease, Crohn’s disease, reactive arthritis, Still’s dis-
ease, idiopathic uveitis and Takayasu arteritis) were regularly
followed in the Rheumatology Outpatient Clinic at the Hos-
pital das Clinicas, Medical School, Universidade de São Paulo.
All patients were treated with anti-TNF agents (adalimumab,
etanercept or inﬂiximab) at the Center of Dispensation of High
Cost Medications (CEDMAC) and were in concomitant use of
disease-modifying antirheumatic drugs (DMARDs).
This study was approved by the Institutional Ethics
Committee, and informed consent was obtained from all par-
ticipants.
Evaluation  of  rheumatic  diseases
The disease activity was assessed using standardized instru-
ments, including the Disease Activity Score (DAS28) for
14tis Disease Activity Index (BASDAI)15 for AS and PsA. The
laboratory parameters were assessed through erythrocyte sed-
imentation rate (ESR), according to the Westergreen method
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1.1 ± 0.6, ESR 18 ± 16 mm/1st h and CRP 10.1 ± 15.4 mg/L. In
patients with AS, mean BASDAI was 3.2 ± 2.6, BASFI 43 ± 32,
ASQoL 6.7 ± 5.4, ESR 8 ± 8 mm/1st h, and CRP 4.3 ± 5, 2 mg/L.
Table 1 – Demographics and treatment data of patients
with rheumatic diseases on anti-TNF therapy.
Variable n  = 194
Demographics
Current age, years 42 ± 16
Male gender, n (%) 68 (35)
Race
White, n (%) 165 (85)
Black, n (%) 16 (8)
Browns, n (%) 14 (7)
Yellow, n (%) 2 (1)
Disease duration, years 15 ± 10
Time of anti-TNF therapy, years 1.9 ± 1.6
Treatment
Anti-TNF
Adalimumab, n (%) 64 (33)
Etanercept, n (%) 59 (30)
Inﬂiximab, n (%) 71 (36)
Glucocorticoids, n (%) 96 (49)
Mean dose, mg/day 7.8 ± 4.6
Methotrexate, n (%) 88 (45)
Average dose, mg/week 22.2 ± 8.6
Leﬂunomide, n (%) 46 (24)
Sulfasalazine, n (%) 24 (12)480  r e v b r a s r e u m a t
(mm/1st hour) and C-reactive protein (CRP) levels by neph-
elometry (mg/L).
The current treatment (concomitant to anti-TNF agent)
with prednisone, DMARDs and immunosuppressant drugs
(methotrexate, azathioprine, leﬂunomide, antimalarial, sul-
fasalazine and/or cyclosporine) was also evaluated.
Evaluation  of  candidiasis  and  risk  factors
Patients were clinically evaluated on the day of application of
anti-TNF therapy for signs and symptoms of infection with
Candida spp., including oral candidiasis, genital candidiasis,
or characteristic dysuria or leucorrhea. Up to four weeks prior
to the study, the following risk factors were analyzed: use of
antibiotics, use of immunosuppressant drugs, hospitalization
and invasive procedures.
1. Fungal peripheral blood culture: Fungal peripheral blood cul-
ture in the population using anti-TNF agent was carried out
with BD BACTECTM-MYCO/F Lytic Medium (Becton Dickin-
son, USA) blood cultures ﬂasks.
2. PCR for Candida spp. in peripheral blood: Detection of Candida
spp. DNA was performed by polymerase chain reaction.16
The analysis of the collected material was held at the Medi-
cal Research Laboratory of Mycology (LIM-53) of HC-FMUSP
in patients undergoing anti-TNF-alpha therapy.
DNA extractions from whole blood samples of those
patients included in this study were performed according to
the technique described by Loefﬂer et al.17 Blood samples
(3–5 ml)  were collected in EDTA tube and subjected to ini-
tial hemolysis with 1.55 M NH4Cl, 100 mM KHCO3, and 10 mM
EDTA pH 7.4. After obtaining the erythrocyte-free cell pel-
let, 3 ml  of a solution containing 100 mM Tris–HCl pH 8.0,
4 M NaCl, and 20 mM EDTA pH 8.2 were added. Next, the
samples were vigorously stirred, and 600 L of a solution
containing TRIS 50 mM,  10 mM EDTA, and lyticase 250 U/ml
(L-4276, Sigma, USA) and 5% -mercaptoethanol were added.
The tubes were kept at 37 ◦C for 2:30 h and after the incuba-
tion period, the extraction of total DNA was performed with
QIAamp® DNA Mini kit (QIAGEN, Germany), according to the
protocol described by the supplier.
As positive controls in ampliﬁcation reactions, DNA sam-
ples of Candida albicans, C. glabrata, C. parapsilosis, C. tropicalis,
C. krusei,  C. lusitaniae and C. pelliculosa were obtained.
For ampliﬁcation of DNA extracted from blood samples
from patients and samples of Candida spp., the technique of
nested-PCR was used. In the ﬁrst ampliﬁcation step, ITS1 and
ITS4 primers were used, and the second stage was designed
for two ampliﬁcation systems, using species-speciﬁc primers:
system 1 comprises primers for C. albicans, C. tropicalis,
C. glabrata and C. lusitaniae; and the system 2, primers for
C. pelliculosa,  C. parapsilosis and C. krusei.Detection of the ampliﬁed systems was carried out in
agarose gels, at 2.5%, electrophoresed in horizontal tanks
Horizon M-58 (Life Technologies, USA), in 1× TAE buffer
(TRIS–acetic acid–EDTA pH 8.0), 80 V for 45 min. After elec-
trophoresis, the gels were stained with GelRedTM (Biotium, 0 1 6;5 6(6):478–482
USA), with results recorded on a photo documentation system
(UVITEC, England).18
Statistical  analysis
The results were presented as mean ± standard deviation (SD)
or median (range) for continuous variables, and as percentage
for categorical variables.
Results
Among the 194 patients included, 67 had RA, 47 had AS, 36
had JIA, 28 had psoriatic arthritis, and 16 had other diag-
noses. The mean age of patients at the time of the study was
42 ± 16 years, with 68 (35%) male; mean disease duration
was of 15 ± 10 years and mean duration of anti-TNF therapy
was use 1.9 ± 1.6 years. As to ethnicity, 85% were Caucasian,
8% black, 7% brown and 1% yellow subjects. Sixty-four (33%)
patients were receiving adalimumab, 59 (30%) etanercept,
and 71 (36%) inﬂiximab. Eighty-one percent of patients were
concomitantly taking immunosuppressant drugs. Regarding
concomitant medications, 96 (49%) used prednisone, 88 (45%),
methotrexate, 46 (24%) leﬂunomide, 24 (12%) sulfasalazine, 10
(5%) cyclosporine, 6 (3%) azathioprine, and 11 (6%) chloroquine
diphosphate (Table 1).
Among patients with RA, mean DAS28 was 3.6 ± 1.5, HAQCyclosporine, n (%) 10 (5)
Azathioprine, n (%) 6 (3)
Chloroquine, n (%) 11 (6)
Data are presented as number (%) and mean ± standard deviation.
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Table 2 – Clinical and laboratory parameters of disease
in patients with rheumatic diseases receiving anti-TNF
therapy.
Variables
Rheumatoid arthritis (n = 67)
DAS28 3.6 ± 1.5
HAQ 1.1 ± 0.6
ESR, mm/1st hour 18 ± 16
CRP, mg/L 10.1 ± 15.4
Ankylosing spondylitis (n = 47)
BASDAI 3.2 ± 2.6
BASFI 43 ± 32
ASQoL 6.7 ± 5.4
ESR, mm/1a hora 8 ± 8
CRP, mg/L 4.3  ± 5.2
Juvenile Idiopathic Arthritis (n = 36)
DAS28 3.4 ± 1.3
ESR, mm/1st hour 15 ± 18
CRP, mg/L 19.5 ± 55.1
Psoriatic arthritis (n = 28)
DAS28 2.5 ± 1.3
BASDAI 3 ± 1.7
ESR, mm/1st hour 10.3 ± 7.8
CRP, mg/L 4.2 ± 4.7
DAS28, Disease Activity Score 28; HAQ, Health Assessment Ques-
tionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive
protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity
Index; BASFI, Bath Ankylosing Spondylitis Functional Index.
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positivity, since this is considered one of the most sensitiveData are presented as number (%) and mean ± standard deviation.
mong patients with JIA, mean DAS28 was 3.4 ± 1.3, ESR
5 ± 18 mm/1st h and CRP 19.5 ± 55, 1 mg/L (Table 2).
At the time of the study, only one (0.5%) patient had local-
zed fungal infection (vaginal candidiasis) and none had oral
hrush. None of the included patients had candidemia with
ositive blood cultures for fungi or PCR positive for Candida
pp. in peripheral blood samples.
The analysis of possible risk factors for Candida infection
evealed that only 14 (7.2%) had received antibiotic therapy
p to four weeks before the evaluation, 9 for respiratory tract
nfection, 3 for cutaneous infection, 1 for urinary tract infec-
ion and 1 for odontogenic infection. Furthermore, no patient
as hospitalized or was subjected to invasive procedures up
o one month prior the study entry.
iscussion
his was the ﬁrst study to assess the prevalence of invasive
nd localized fungal disease caused by candida in a signiﬁcant
umber of patients with rheumatic diseases treated with anti-
NF therapy, showing low risk of candidiasis, despite the high
revalence of immunosuppressive drugs use.
Epidemiological studies have shown a considerable
ncrease in infections in immunocompromised patients,
ncluding Candida spp., particularly in nosocomial sepsis, with high mortality rate. Candida albicans is considered as a com-
ensal member of the normal ﬂora of the digestive tract
nd its pathogenicity is the result of alterations in host 6;5 6(6):478–482 481
defense mechanisms that induce behavioral changes of the
fungus.19,20
Patients with rheumatic diseases are often exposed to
several risk factors associated with a signiﬁcant increase in
fungal infection incidence in recent decades. The use of broad-
spectrum antibiotics can cause changes in mucosal ﬂora,
leading to the proliferation of candida; corticosteroids can
affect the activity of polymorphonuclear cells, macrophages
and T cells; surgical procedures and the use of immunosup-
pressive drugs, particularly biologicals, facilitate the spread
of opportunistic pathogens.2,21 Actually, in the published
literature, in 98% of invasive fungal infections such as histo-
plasmosis, candidiasis and aspergillosis, the use of at least one
immunosuppressive agent, particularly corticosteroids, asso-
ciated with anti-TNF therapy, was reported.1
Innate immune response is the dominant mechanism
responsible for yeast clearance after an initial systemic
infection. Monocytes and macrophages are the cells most
associated with response against systemic infection with
C. albicans. The pathways by which this event occurs are not
entirely clear, but appear to involve recognition of pathogen-
associated molecular patterns (PAMPs) on the yeast mediated
by phagocytic cell receptors, resulting in activation and release
of inﬂammatory cytokines.19 Furthermore, the spectrum
of defenses against mucocutaneous and systemic candidal
infection includes cell-mediated immunity which is charac-
terized by the release of cytokines by lymphocytes and by the
activation of NK cells and lymphocytes by interleukins. How-
ever, there is evidence to support the role of humoral response
in the protection against invasive Candida infection.19,20
It is known that, in cases of systemic infection with C.
albicans, TNF production is stimulated by the pathogen. Louie
et al.22 demonstrated, in an animal model of systemic can-
didiasis, that this cytokine has a protective role in infection.
The neutralization of TNF activity would lead to suppression
of the production of IFN, promotion of monocyte apoptosis
and prevention of maintenance of granuloma, allowing fun-
gus growth in several organs.1 Indeed, in a review of studies
on invasive fungal infections associated with anti-TNF ther-
apy (inﬂiximab, adalimumab, etanercept) in various diseases
(graft vs. host disease, inﬂammatory bowel disease and RA)
between 1966 and 2007, Tsiodras et al.1 found 281 cases. Can-
didiasis was responsible for 23% of infections and, of these,
only 3 occurred in patients with RA. Although evidence in the
literature suggests that there may be differences regarding
the risk of infection among different anti-TNF drugs,23 the
present study showed low frequencies of candidiasis for the
three agents used.
Moreover, among patients with rheumatic diseases there
are only two septic arthritis reports by Candida spp. in patients
with rheumatoid arthritis in anti-TNF therapy.8,9 However, in
both cases, the concomitant use of other immunosuppressive
agents may have contributed to the development of candida
infection.
The PCR methodology used for the detection of Candida
spp. in this study does not appear to justify the absence ofmodalities for diagnosing candidemia, compared to tradi-
tional methods.24 In a study of mice with induced candidemia,
the sensitivity of this technique was 79%.25 On the other hand,
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the fungal isolation in culture of sterile ﬂuid such as blood
and peritoneal ﬂuid is associated with a low recovery rate,
reaching only a positivity of 40–60% in patients with systemic
candidiasis conﬁrmed by autopsy.26
From this study, we concluded that invasive and local-
ized fungal disease by candida did not represent a common
infection in patients with rheumatic diseases with immuno-
suppressive therapy associated with anti-TNF agents.
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